1393841-41-2

Usage

Uses

Used in Dermatology:
C₃₄H₃₇FO₄ is used as a topical anti-inflammatory and anti-itching agent for the treatment of various skin conditions such as eczema, psoriasis, and allergic reactions. Its application helps in reducing inflammation, suppressing the immune response, and relieving itching and swelling.
Used in Topical Creams, Ointments, and Gels:
C₃₄H₃₇FO₄ is used as an active ingredient in topical formulations like creams, ointments, and gels for direct application to the skin. These formulations allow for targeted treatment of affected areas, minimizing systemic side effects and ensuring effective relief from skin conditions.
Overall, fluocinolone acetonide (C₃₄H₃₇FO₄) is a valuable compound in the field of dermatology, providing effective relief from various skin conditions with minimal side effects when used as directed.

Upstream product

• 14348-41-5 3-bromo-4-hydroxy-benzoic acid 
• 4541-32-6 2,2-dimethylcyclopentanone 
• 100-83-4 meta-hydroxybenzaldehyde 
• 1011531-89-7 2-(5,5-dimethylcyclopent-1-en-1-yl)-4,4,5,5-tetramethyl-1 ,3 ,2-dioxaborolane 
• 153580-03-1 5,5-dimethylcyclopent-1-en-1-yl trifluoromethanesulfonate 
• 1142224-60-9 3-cyclopropyl-3-(3-hydroxyphenyl)propanoic acid 
• 1142223-02-6 5-(cyclopropyl(3-hydroxyphenyl)methyl)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 15795-58-1 5-((3-hydroxyphenyl)methylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 59939-11-6 methyl (E)-3-cyclopropylpropenoate 
• 1142223-37-7 4-(chloromethyl)-2-(5,5-dimethyl-1-cyclopenten-1-yl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl 
• 1142223-08-2 methyl (3S)-3-cyclopropyl-3-(3-hydroxyphenyl)propanoate 
• 1142223-31-1 (2-(5,5-dimethyl-1-cyclopenten-1-yl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-4-yl)methanol 
• 1142224-47-2 methyl 2-(5,5-dimethylcyclopent-1-en-1-yl)-2'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-carboxylate 
• 1142224-45-0 methyl 3-(5,5-dimethylcyclopent-1-enyl)-4-(trifluoromethylsulfonyloxy)benzoate 

Downstream Products

• 1142214-62-7 [3H]-AM 1638 

Relevant academic research and scientific papers

Improving the pharmacokinetics of GPR40/FFA1 full agonists

We recently reported the discovery of a potent GPR40 full agonist AM-1638 (1). Herein, we describe our efforts in improving the drug-like properties of the full agonists through the systematic introduction of polar groups in the C-, D-, and A-rings. This led to the discovery of new GPR40 full agonists with significantly improved pharmacokinetic propeties. Compound 8 and 20 also showed potent in vivo efficacy in oral glucose tolerance tests in mice in addition to the improvement in properties.

Discovery of AM-1638: A potent and orally bioavailable GPR40/FFA1 full agonist

GPR40 (FFA1) is a G-protein-coupled receptor, primarily expressed in pancreatic islets, the activation of which elicits increased insulin secretion only in the presence of elevated glucose levels. A potent, orally bioavailable small molecule GPR40 agonist